L
Lucid Diagnostics Inc. (LUCD)
NCM – Real vaqt narxi. Valyuta: USD
1.04
+0.02 (1.96%)
Yopilishda: May 12, 2026, 4:00 PM EDT
1.04
0.00 (0.00%)
Bozordan keyin: May 12, 2026, 4:10 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
1.04
+0.02 (1.96%)
Yopilishda: May 12, 2026, 4:00 PM EDT
1.04
0.00 (0.00%)
Bozordan keyin: May 12, 2026, 4:10 PM EDT
Lucid Diagnostics Inc. Qo'shma Shtatlarda tijoriy bosqichdagi tibbiy diagnostika texnologiyasi kompaniyasi sifatida faoliyat yuritadi. U oshqozon-qizilo'ngach reflyuks kasalligi (GERD) bilan og'rigan bemorlarga qaratilgan bo'lib, ular oshqozon o'simtasi va saratoni, birinchi navbatda, o'limga olib keluvchi oshqozon adenokarsinomasi rivojlanish xavfi ostida turadi. Kompaniyaning asosiy mahsuloti, EsoCheck Oshqozon hujayralarini yig'ish moslamasi yordamida to'plangan namunalarda bajariladigan EsoGuard Oshqozon DNK Testi, bu xavf ostidagi GERD bemorlarida oshqozon oldi saratonini erta aniqlash orqali EAC o'limlarini oldini olish maqsadini ko'zlagan test vositasidir. Kompaniya 2018 yilda tashkil etilgan va Nyu-York, Nyu-Yorkda joylashgan. Lucid Diagnostics Inc. PAVmed Inc. sho'ba korxonasi sifatida faoliyat yuritadi.
| Ism | Lavozim |
|---|---|
| Dr. Amitabh Chak M.D. | Co-Founder & Strategic Advisor |
| Dr. Brian J. deGuzman M.D. | Chief Technology & Compliance Officer |
| Dr. Joseph Willis M.D. | Co-founder & Strategic Advisor |
| Dr. Lishan Aklog M.D. | Chairman & CEO |
| Dr. Sanford D. Markowitz M.D., Ph.D. | Co-Founder & Strategic Advisor |
| Dr. Suman M. Verma M.D., Ph.D. | Senior VP & Chief Scientific Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | DEF 14A | formdef14a.htm |
| 2026-04-24 | 8-K | form8-k.htm |
| 2026-04-23 | 8-K | form8-k.htm |
| 2026-04-20 | PRE 14A | formpre14a.htm |
| 2026-04-03 | S-8 | forms-8.htm |
| 2026-03-25 | 10-K | lucd20251231_10k.htm |
| 2025-12-05 | S-3 | forms3.htm |
| 2025-11-12 | 10-Q | form10-q.htm |
| 2025-09-25 | 8-K | form8-k.htm |
| 2025-09-11 | 8-K | form8-k.htm |
| Helen Moinova Ph.D. | Co-Founder & Strategic Advisor |
| Mr. Matthew Riley | Director of Investor Relations |
| Mr. Michael Adam Gordon | General Counsel & Secretary |
| Mr. Shaun M. O'Neill M.B.A. | President & COO |